Strainprint Helps Consumers Figure Out if Their Cannabis Actually Works for Them

Making the choice to use medical marijuana is easy — but deciding how to go about using it is the hard part. With so much out there with regard to strain varieties and product selection, from joints to gel caps and so forth, it can be difficult for patients to discern not only what they should use, but also how well it's working for them. 

That's why Stephanie Karasick, founder of Strainprint, began keeping a cannabis tracking journal when she started to use medical marijuana in Canada. And that's how Strainprint was born: to track patient results vis-a-vis different cannabis products in order to find the best efficacy to give the best patient outcomes. 

Within the first year of launching the app in 2016, Strainprint garnered nearly 400,000 patient reported outcomes. Now they're up to 1.4 million, with tens of thousands of patients. The app now has tracked more than 65 million data points to foster a comprehensive take on patient reported outcomes — defined by when a patient uses cannabis against a certain symptom or a certain condition. The app allows patients to record how they were feeling before they tried the cannabis product and after, on a scale of 1 to 10, so they can better grasp the extent to which it helps them. 

Strainprint is aptly suited for a cannabis-legal context. If you're a patient in Canada or Florida, Strainprint has pre-populated the product  chemical constituents in the app, which then keeps track of all the lane verified cannabinoids, flavonoids and terpenes available. The app is available North America-wide and you are able to add your product when tracking sessions.

Therefore, the app is able to collect data about how different types of products, or combinations of cannabis compounds, are able to best treat specific conditions. At the same time, Strainprint is totally HIPAA and PIPEDA compliant, so as to ensure patient privacy. 

"Our app pushes the industry as a whole to go further into the science than just THC and CBD ratios," says Kashton Foley, marketing manager at Strainprint. "Another large factor in a reported outcome is the method of ingestion, and we're seeing in our data that method of ingestion does matter." 

After a patient has tracked multiple sessions, they can also get a personalized snapshot of what's working for them in particular. That way, the next time they go to the clinic or dispensary, they'll know the chemical profile they're seeking in whatever cannabis products they're perusing. 

In collecting this mountain of data, Strainprint has also been able to pursue a number of clinical study partnerships, currently focused in Florida and Canada. The app also has lent itself to a number of research reports, for use by medical cannabis practitioners and industry stakeholders, and which also comprise what Foley calls "the largest study of Cannabis product use and efficacy in the world." 

With all the collected product data, Strainprint can tell a story to push the industry forward and provide a better understanding of which products or kinds of cannabinoid and terpene ratios work best. 

Strainprint’s raison d’etre is to "use cannabis better," to allow patients to take charge of their medicine. After all, Strainprint was founded by patients by patients, and they are working to push the scientific understanding of Cannabis as a medicine forward, through data.  

Latest.

Few other entrepreneurs in the cannabis space have their hands in quite as many ventures as Lorne Gertner. Currently dubbed the "godfather of the Canadian cannabis industry," Gertner told Civilized, "If we could live through normalization, we could change the world." Hailing from the fashion industry, this Toronto native says he's on a mission to "make the world a better place through cannabis and design excellence." The only catch is, well, normalizing cannabis — and that's where Gertner's keen eye for style comes in. "In the old days, you were going to be different or you were going to be normal," said Thom Antonio, Gertner's friend, creative director, and collaborator of 35 years.

Can we see some ID please?

You must be 19 years of age or older to enter.